Davide Capodanno, Giuseppe Giacchi, Corrado Tamburino
{"title":"新型口服抗凝剂(NOACs)逆转剂的现状及发展趋势。","authors":"Davide Capodanno, Giuseppe Giacchi, Corrado Tamburino","doi":"10.2174/15748901112079990013","DOIUrl":null,"url":null,"abstract":"<p><p>Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds. </p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":"8 1","pages":"2-9"},"PeriodicalIF":0.0000,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).\",\"authors\":\"Davide Capodanno, Giuseppe Giacchi, Corrado Tamburino\",\"doi\":\"10.2174/15748901112079990013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds. </p>\",\"PeriodicalId\":20905,\"journal\":{\"name\":\"Recent patents on cardiovascular drug discovery\",\"volume\":\"8 1\",\"pages\":\"2-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on cardiovascular drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/15748901112079990013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/15748901112079990013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).
Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
